Sign In

Dave Sheppard, CMAA

Global M&A, OutSourced B,D&L Leader for SME (Small and Medium Enterprises) & Emerging Technology Healthcare Companies

Dave Sheppard, CMAA is a prominent figure in the medical device and healthcare technology industry, serving as the Managing Director and Co-Founder of MedWorld Advisors.1 With over 30 years of experience in the medical device industry, he has established himself as a leader in mergers and acquisitions (M&A) transactions and organic growth strategies for companies of various sizes.3

Key aspects of Dave Sheppard's professional profile include:

Experience and Expertise

  • Leadership Roles: He has held President, General Manager, and Vice President positions in companies of various sizes, including Covidien.1
  • M&A Specialist: Sheppard has been involved in both sell-side and buy-side M&A activities for over 20 years, successfully driving EBIT growth through these transactions.1
  • International Business: He has completed distribution and licensing deals with over 150 international businesses across 28 countries, working with both major Fortune 500 companies and smaller entities.1

MedWorld Advisors

As the Managing Director and Co-Founder of MedWorld Advisors, Sheppard leads a team that specializes in:

  • Mergers and acquisitions in the medical device, biotech, and OEM medtech industries
  • Business development
  • Financial advisory services

The company focuses on helping small- and medium-sized medical device and technology companies accelerate innovation and growth.2

Professional Certifications and Skills

  • Certified Merger & Acquisition Advisor (CMAA)3
  • Expertise in organic growth strategies
  • Proficiency in navigating global markets and regulatory environments2

Industry Involvement

Sheppard is actively involved in industry discussions and thought leadership:

  • He contributes articles to industry publications such as Medical Product Outsourcing magazine.4
  • Participates in podcasts and interviews, sharing insights on topics like launching medical devices internationally.2

Dave Sheppard's extensive experience, global network, and specialized knowledge in the medical device and healthcare technology sectors make him a valuable resource for companies seeking growth, expansion, or strategic partnerships in these industries.

Highlights

Mar 13 · linkedin

MedWorld Advisors is excited to once again be representing our clients (and meeting new ones) with major strategics @ BIO-EUROPE Spring in Barcelona next week. I'm looking forward to seeing friends, clients, and business acquaintances on March 18–20, 2024. Informa Connect Johnson & Johnson Boehringer Ingelheim Bayer IQVIA Roche Merck Bristol Myers Squibb Eli Lilly and Company GSK

#Medworld #strategicpartnerships #mergersandacquisitions David Cheung Wissam Abousleiman Michael Gentile Estelle Black Florence Joffroy-Black CMAA Florence Henry-Leroux Jeremy Thomas MBA Ryan⭐ Stellar Eric S. Heinz, MBA #barcelona

Dec 27 · linkedin

With all due respect, Amanda Pedersen has lost perspective of the patient. As a 60+ male who can benefit from LDT's (for example - Prostrate), I am disappointed by the lack of true investigation into this topic. Going deeper, (as an example) if you review the current state of Prostrate diagnosis today, the standard of care is PSA. I challenge anyone with integrity to factually state that PSA is accurate and reliable.

With LDT's being created that can provide someone like me a more accurate understanding of my potential prostrate cancer status, I am grateful that innovators are working on these types of solutions AND making them available via CLIA labs. My father was diagnosed with Prostrate cancer - due to PSA tests - and (my personal opinion) suffered needlessly on a premature basis due to this diagnosis. He later passed away due to bladder cancer (another topic altogether).

Ms. Pederson seems to suggest that the FDA will make access to LDT's available in a reasonable manner. However, history suggests that the FDA is not easy to work with - when it comes to newer technologies that they do not understand. In this case, I am suggesting that liquid biopsies are an answer to prayer for many potential cancer patients. As an example, see the success that Guardant Health has achieved in lung cancer.

In summary, please do not complicate my (as a patient) access to care. Please advocate for my ability to make my own choices. Otherwise, I may die before the FDA makes a "reasonable determination" on these types of new technologies.

With sincere respect and desire for patient advocacy..... Cheers - Dave Sheppard, CMAA

Related Questions

What are some of Dave Sheppard's most notable achievements in the medical device industry?
How did Medworld Advisors come into existence?
What challenges does Dave Sheppard face in his role at Medworld Advisors?
How does Medworld Advisors differentiate itself from other M&A firms?
What strategies does Dave Sheppard use to help small medical device companies grow?
Dave Sheppard, CMAA
Dave Sheppard, CMAA, photo 1
Dave Sheppard, CMAA, photo 2
Add to my network

Location

United States